ArticleInternational microbiology : the official journal of the Spanish Society for Microbiology2022
Characteristics and growth kinetics of biomass of Citrobacter freundii strains PYI-2 and Citrobacter portucalensis strain YPI-2 during the biodegradation of Ibuprofen.
Article in International microbiology : the official journal of the Spanish Society for Microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 11 citations in OpenAlex.
- Removal of Ibuprofen from Contaminated Water by Bioaugmentation with Novel Bacterial Strains Isolated from Sewage Sludge.Microorganisms · 2025Article
- Genetic and species rearrangements in microbial consortia impact biodegradation potential.The ISME journal · 2025Article
- Recent advances in degradation of N,N-diethyl-3-toluamide (DEET)-an emerging environmental contaminant: a review.Environmental monitoring and assessment · 2024Review
- Evaluation of the Defined Bacterial Consortium Efficacy in the Biodegradation of NSAIDs.Molecules (Basel, Switzerland) · 2023Article
- Ibuprofen: Toxicology and Biodegradation of an Emerging Contaminant.Molecules (Basel, Switzerland) · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ibuprofen (IBU) is the third most commonly used analgesic drug in the world. It enters the water system as a result of human excretion-based wastewater discharges. Hence, it attracts the attention of environmentalists for its ecological fate and degradation behavior. In this study, the two IBU degrading bacterial strains, Citrobacter freundii strain PYI-2 (MT039504) and Citrobacter portucalensis strain YPI-2 (MN744335), were isolated from industrial wastewater samples using an enrichment culture method, identified, and characterized. Physiological and batch culture degradation studies have indicated that these strains involved in IBU degradation and the intermediates produced during the process were analyzed. These strains degrade IBU in the batch culture. The optimum pH was reported for degradation of the PYI2 strain (6.9) and YPI2 strain (5.8), and the optimum temperatures were 42°C and 32°C, respectively. Biomass kinetic analysis of these strains was performed based on physical parameters (temperature, pH, and rpm) and confirmed by the experimental study. As indicated in the GC-MS chromatogram peaks, viz., hydroxyibuprofen, 2-(4-hydroxyphenylpropionic acid), 1,4-hydroquinone, and 2-hydroxy-1,4-quinol various intermediates compounds of degradation pathway were observed. Finally, through the GC-MS data, the metabolic pathway for degradation was predicted. In the study, it was confirmed that Citrobacter freundii strain PYI-2 and Citrobacter portucalensis strain YPI-2 exhibit metabolic potential for the biodegradation of IBU and can be further deployed in bioremediation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.